@article{TCR34144,
author = {Bei Wang and Xiaoyan Zhang and Huang Chen and Lei Yang and Jie Li and Fei Xiao and Chaoyang Liang and Dingrong Zhong},
title = {The clinicopathological study of lung cancer concealed in end-stage of interstitial lung disease},
journal = {Translational Cancer Research},
volume = {9},
number = {2},
year = {2019},
keywords = {},
abstract = {Background: Most of the patients with interstitial lung disease (ILD) complicated with lung cancer (ILD- LC) showed non-specific clinical manifestations. This study is to explore the incidence of lung cancer concealed in the end-stage of interstitial lung disease (LC-CES-ILD).
Methods: A total of 154 cases of lung transplantation from March 2017 to December 2018 were studied retrospectively, of which 7 cases were found to be LC-CES-ILD. Serum tumor biomarkers were examined. HE and immunohistochemical staining were performed for the tumor tissue after the operation. Lung cancer (LC) drive gene was detected by quantitative real-time polymerase chain reaction (qRT-PCR).
Results: The percentage of male patients with idiopathic pulmonary fibrosis (IPF) was 44.81%. The expression of all tumor biomarkers was significantly increased in 6 patients with LC-CES-ILD. After operation, apparent destruction of lung tissue structure was observed in 7 patients, and honeycomb appearance could be seen in some areas. After HE staining, 4 cases of acinar type and 2 cases of mucinous adenocarcinoma were found. The results of molecular pathology showed that only one case of mucinous adenocarcinoma had KRAS mutation, and no mutation of LC co-driving gene was found in the rest of the cases.
Conclusions: It is necessary to detect the lung tissue of patients with end-stage ILD, which were probably correlated with the occurrence of LC concealed, before lung transplantation.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/34144}
}